Santhera Pharmaceuticals Holding AG
SANN
Kedudukan dalam Saham
#16594
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Harga Saham
$17.23
Modal Pasaran
$263.68M
Perubahan (1 hari)
-4.18%
Perubahan (1 tahun)
38.54%
Negara
CH
Perdagangan Santhera Pharmaceuticals Holding AG (SANN)
Kategori
Healthcare
Sejarah harga saham bagi Santhera Pharmaceuticals Holding AG (SANN)
Harga penutupan tertinggi: $18.92 pada 2026-10-01
Harga penutupan terendah: $44.13 pada 2014-03-01
Harga penutupan terendah: $44.13 pada 2014-03-01
Sejarah harga saham Santhera Pharmaceuticals Holding AG dari 2014 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2026 (TTM) | 22.24% |
| 2025 | 42.98% |
| 2024 | -6.16% |
| 2023 | 41.12% |
| 2022 | -43.82% |
| 2021 | -53.14% |
| 2020 | -74.39% |
| 2019 | -17.31% |
| 2018 | -49.89% |
| 2017 | -38.99% |
| 2016 | -48.52% |
| 2015 | -16.32% |
| 2014 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $536.73 | 25.86% |
US
|
|
| $225.94 | 741.49% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $878.85 | 7.94% |
NL
|
